TITLE

High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention

AUTHOR(S)
Suk Min Seo; Eun-Ho Choo; Yoon-Seok Koh; Mahn Won Park; Dong II Shin; Yoon Seok Choi; Hun-Jun Park; Dong Bin Kim; Sung Ho Her; Jong Min Lee; Chul Soo Park; Pum-Joon Kim; Keon Woong Moon; Kiyuk Chang; Hee Yeol Kim; Ki Dong Yoo; Doo Soo Jeon; Wook Sung Chung; Yong Gyu Park; Ki-Bae Seung
PUB. DATE
December 2011
SOURCE
Heart;Dec2011, Vol. 97 Issue 23, p1943
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A low level of high-density lipoprotein cholesterol (HDL-C) is strongly associated with cardiovascular events. However, the significance of HDLC after statin therapy on the outcome of patients who have undergone percutaneous coronary intervention (PCI) with drug eluting stents (DES) is unclear. Objectives: To investigate the significance of HDL-C after statin therapy on cardiovascular events in patients with coronary artery disease after DES implantation. Methods: Patients who underwent PCI with DES from January 2004 to December 2009 were prospectively enrolled. The follow-up lipid panel of 2693 patients (median lab follow-up duration 225 days) who had continued using statins after PCI and who attained lowdensity lipoprotein cholesterol (LDL-C) <100 mg/dl was analysed. Major adverse cardiac events (MACE), including all-cause death, non-fatal myocardial infarction, and target vessel revascularisation according to follow-up HDL-C level (40 mg/dl for men or 50 mg/dl for women) were compared with the use of propensity scores matching. Results: Median follow-up duration was 832 days. 1585 (58.9%) patients had low follow-up HDL-C and 1108 had high follow-up HDL-C. The low follow-up HDL-C group had significantly higher rates of MACE. Low follow-up HDL-C was a significant independent predictor of MACE (adjusted HR 1.404, 95% CI 1.111 to 1.774, p=0.004). In further analysis with propensity scores matching, overall findings were consistent. Conclusions: Raising HDL-C levels may be a subsequent goal after achieving target LDL-C levels in patients with DES implantation.
ACCESSION #
68637792

 

Related Articles

  • RESEARCH & TECHNOLOGY.  // MondayMorning;12/5/2011, Vol. 19 Issue 44, p13 

    The article presents a study that suggests that people with low levels of good cholesterol are more likely to have heart attacks. It offers an analysis of a data that confirms the linkage between low levels of high-density lipoprotein (HDL) and raised heart attack risk in mass population....

  • Lipid-lowering therapy in patients with peripheral arterial disease. Collins, P.; Brittenden, J. // Vascular Medicine;2004, Vol. 9 Issue 4, p303 

    The article presents information on the impact of lipid-lowering therapy in patients with peripheral arterial disease. It states that epidemiological, post mortem and angiographic studies have consistently shown a strong positive correlation between plasma total cholesterol and the incidence of...

  • High-dose atorvastatin was superior to standard-dose pravastatin for reducing death or major cardiovascular events in acute coronary syndromes. Hillegass, William B.; Alam, Golam K. // ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p33 

    This article focuses on alternate treatment of patients with Acute Coronary Syndrome (ACS). Researchers investigated that a standard-dose of pravastatin is noninferior to high-dose atorvastatin for reducing death or major cardiovascular events. 4162 patients (mean age 58 y, 78% men) in stable...

  • Study: The Higher the Co-Pay, the Lower the Chance That Heart Patients Stay on Cholesterol-Lowering Drugs; Even Among Those Who Need Them Most, Statin Prescriptions Go Unfilled.  // Ascribe Newswire: Medicine;6/14/2004, p77 

    Tens of millions of people in the U.S. take cholesterol-lowering drugs every day to keep their blood vessels clear and reduce their risk of heart attacks and other cardiovascular problems. A new study finds that nearly half of patients who have a prescription for any of the cholesterol-fighting...

  • Statin Therapy for Native and Peri-Interventional Coronary Heart Disease. Smith, D. A.; Galin, I. // Current Molecular Medicine;Aug2006, Vol. 6 Issue 5, p589 

    Atherosclerosis is a slow, complex process involving many different cell types and their interactions producing excessive oxidant stress, increased inflammation, abnormal endotheliumdependent vasodilation, and localized increases in thrombogenic and decreases in fibrinolytic factors. Numerous...

  • Statin Therapy and the Outcomes during Hospitalization for Acute Coronary Syndromes.  // Annals of Internal Medicine;6/1/2004, Vol. 140 Issue 11, p29 

    This article presents information on statin therapy and the outcomes during hospitalization for acute coronary syndromes. Acute coronary syndromes involve blockages in blood flow to heart muscle. If the blockage lasts long enough, an area of heart muscle dies, a condition commonly known as a...

  • Hyperlipidaemia --part one.  // GP: General Practitioner;11/18/2002, p47 

    Reports that lowering total cholesterol is effective in the prevention of coronary heart diseases (CHD). Significance of statins in preventing coronary diseases; Primary and secondary prevention of CHD; Role of lovastatin in preventing CHD.

  • Beneficial Effects of Statin Therapy on Survival in Hypertensive Patients With Acute Myocardial Infarction: Data From the RICO Survey Sicard, Pierre; Zeller, Marianne; Dentan, Gilles; Laurent, Yves; Touzery, Claude; L’huillier, Isabelle; Janin-Manificat, Luc; Lorgis, Luc; Beer, Jean-Claude; Makki, Hamib; Rochette, Luc; Cottin, Yves // American Journal of Hypertension;Nov2007, Vol. 20 Issue 11, p1133 

    Background: Randomized studies have shown a reduction in cardiovascular events associated with low doses of statin among hypertensive patients at only moderate cardiovascular risk. The hypothesis of the present study was that statin therapy initiated during hospitalization could improve the...

  • Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. Zheng Zhou; Rahme, Elham; Abrahamowicz, Michal; Tu, Jack V.; Eisenberg, Mark J.; Humphries, Karin; Austin, Peter C.; Pilote, Louise // CMAJ: Canadian Medical Association Journal;4/26/2005, Vol. 172 Issue 9, p1187 

    Background: Clinical trials have shown the benefits of statins after acute myocardial infarction (AMI). However, it is unclear whether different statins exert a similar effect in reducing the incidence of recurrent AMI and death when used in clinical practice. Methods: We conducted a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics